预约演示
更新于：2025-04-17
Botulinum toxin(UroGen Pharma Ltd.)
更新于：2025-04-17
概要
基本信息
非在研机构- |
最高研发阶段临床2期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
关联
33
项与 Botulinum toxin(UroGen Pharma Ltd.) 相关的临床试验ChiCTR2400080899
Study on the Safety and Efficacy of Extracorporeal Shock Wave Combined with Botulinum Toxin in the Treatment of Children with Spastic Cerebral Palsy
开始日期2024-02-19 |
申办/合作机构- |
IRCT20230408057842N2
Exploring Intragastric Botulinum Toxin Injections: A Prospective study on the rate of Weight Loss in Overweight and Obese Patients
开始日期2023-11-06 |
IRCT20130523013442N33
Comparison of ultrasound guided injection of botulinum toxin at the origin of plantar fasciitis with injection of botulinum toxin by Babcock method in the treatment of plantar fasciitis
开始日期2023-09-23 |
100 项与 Botulinum toxin(UroGen Pharma Ltd.) 相关的临床结果
登录后查看更多信息
100 项与 Botulinum toxin(UroGen Pharma Ltd.) 相关的转化医学
登录后查看更多信息
100 项与 Botulinum toxin(UroGen Pharma Ltd.) 相关的专利（医药）
登录后查看更多信息
3,424
项与 Botulinum toxin(UroGen Pharma Ltd.) 相关的文献（医药）2025-05-01·Physical Medicine and Rehabilitation Clinics of North America
Pelvic Pain and Pelvic Floor Disorders in Women
Review
作者: Laurenzana, Lisa ; Fitzgerald, Colleen ; Bennis, Stacey
Pelvic pain is a complex diagnosis that can be related to numerous etiologies across several specialties. This chapter aims to explore diagnosis and management of common neuromusculoskeletal causes of pelvic pain including pelvic floor myofascial pain, vulvodynia, nerve injuries, pelvic girdle pain, and coccydynia. Pelvic floor physical therapy is often the first-line treatment of many musculoskeletal causes of pelvic pain. Depending on examination findings, diagnosis, and response to physical therapy, additional medical management may include neuromodulation in oral or topical form, vaginal muscle relaxants, or pelvic floor botulinum toxin or trigger point injections.
2025-05-01·LARYNGOSCOPE
Turbinate Injection of Botulinum Toxin in the Treatment of the Chronic Rhinitis
Review
作者: Hwang, Se H. ; Kim, Do H. ; Jang, David W.
Objectives:
This systemic review with meta‐analysis evaluated the effect of intranasal BTX‐A turbinate injection on chronic rhinitis‐related symptoms.
Data Sources:
PubMed, SCOPUS, Embase, Web of Science, and Cochrane databases.
Review Methods:
We reviewed studies retrieved from databases up to Aug 2024. The studies evaluating the degree of change of rhinitis‐related symptom scores and quality of life before and after BTX‐A injection were analyzed. Standard mean differences were used to calculate effect sizes.
Results:
A total of 269 patients from 7 studies were analyzed. BTX‐A injection showed a significant improvement in rhinitis‐related symptoms (congestion: 2.5416, 95% CI 1.0927–3.9905, I2 = 94.4%, itching: 1.2553, 95% CI 0.6660–1.8446; I2 = 70.8%, rhinorrhea: 1.8451, 95% CI 1.0468–2.6435, I2 = 89.7%, and sneezing: 1.3580, 95% CI 0.5194–2.1967; I2 = 90.7%), total nasal symptom score (2.4020, 95% CI 1.4161–3.3879, I2 = 86.1%), and quality of life (1.5256, 95% CI 1.0760–1.9752; I2 = 0.0%) throughout the follow‐up period (4 months). However, 3 months after injection, although symptom improvement remained, there was no statistical significance. Allergic rhinitis (AR) patients showed a significant improvement in rhinitis‐related symptoms compared with nonallergic rhinitis (NAR) patients.
Conclusions:
Nasal symptoms and quality of life scores related to rhinitis were decreased after BTX‐A injection. In particular, this treatment showed better efficacy in AR and could be more beneficial for the symptoms of nasal congestion and rhinorrhea at the early periods of treatment. However, the effects lasted for a relatively short period of only 2–3 months. Laryngoscope, 135:1545–1552, 2025
2025-05-01·ARCHIVES OF ORAL BIOLOGY
Botulinum toxin type A inhibits hyperalgesia in the rat masseter muscle in a carrageenan model of myofascial pain
Article
作者: Casais-E-Silva, Luciana Lyra ; Aguiar, Marcio Cajazeira ; Neves, Ilana Dantas ; Pinho, Pedro Paulo Pereira
OBJECTIVE:
Previous studies have shown that botulinum toxin type A (BoNT-A) attenuates nociception, but the underlying mechanisms remain unclear. Studies of experimental pain in humans have also shown conflicting results. Carrageenan is commonly used to produce short-term acute inflammation and hyperalgesia in animal models, and the effect of BoNT-A on carrageenan-induced pain in the masseter muscle has not been studied. This study evaluated the antinociceptive and anti-inflammatory effects of intramuscular injection of BoNT-A in an experimental model of inflammatory pain in the masseter muscle of rats.
DESIGN:
Carrageenan (2 %) was injected into the masseters of sixty rats pretreated with three sessions of BoNT-A (3.5 U/kg) or daily with ibuprofen (40 mg/kg) for seven days. Masseter injected with saline was used as a control. An electronic von Frey anesthesiometer determined the head withdrawal threshold before carrageenan and at 5 h, 1, 3, and 7 days following administration. The masseters were processed for paraffin embedding and H&E staining and subjected to histomorphometric analysis 1 and 8 days after carrageenan administration.
RESULTS:
Pretreatments with BoNT-A or ibuprofen significantly decreased carrageenan-induced hyperalgesia. BoNT-A did not inhibit inflammation and tissue damage induced by carrageenan.
CONCLUSIONS:
These findings reveal that BoNT-A promotes antinociceptive effects in the masseter muscle during painful conditions independently of anti-inflammatory mechanisms.
6
项与 Botulinum toxin(UroGen Pharma Ltd.) 相关的新闻（医药）2024-11-21
NEWS RELEASE: Merz Therapeutics and S3 Connected Health Pioneer New Digital Health Solution, iFlexo, for People Living with Post-Stroke Spasticity
Dublin/Frankfurt — Merz Therapeutics launches iFlexo, a personalized digital solution aimed at enhancing rehabilitation for people with post-stroke spasticity as part of its ongoing commitment to supporting stroke survivors.
The app, developed in collaboration with S3 Connected Health, provides targeted exercises and rehabilitation programs specifically aimed at improving mobility for those with mild to moderate spasticity. By offering guided routines, iFlexo aims to help stroke survivors regain independence and improve their overall quality of life. Merz Therapeutics is the first and only neurotoxins pharmaceutical company to offer a platform to support self-rehabilitation.
iFlexo, developed and operated on S3 Connected Health’s digital health platform Affinial, was released in August 2024 and is available for iOS and Android in France. Developing iFlexo on Affinial enabled the creation of a differentiated user experience optimized for post-stroke patients. An accelerated time to market of just five months was achieved thanks to Affinial’s range of pre-built, customizable digital health services. The Affinial platform enables iFlexo to scale and evolve by addressing current and future compliance, legal, cybersecurity, and regulatory requirements. During the pilot stage in France, it gained significant interest from patients, clinicians, and key opinion leaders.
Dr. Alexandre Bertholon, Physical Medicine & Rehabilitation at Le Clos Champirol, says: “iFlexo is a promising solution in physical rehabilitation, offering a much-needed response to the current challenges in the field. It enables patients to engage in self-rehabilitation at home, focusing on their personal goals. This platform not only supports patients but also enhances efficiency for healthcare professionals by optimizing and extending the results of rehabilitation. It demonstrates how new solutions can improve patient outcomes and make care more effective.”
Up to one-third of stroke survivors experience spasticity, a condition that can severely limit their ability to perform everyday tasks, often leaving them reliant on others.[1] For these individuals, personalized botulinum neurotoxin injection therapy as part of a multimodal approach can improve muscle tone and consequently patient’s mobility and quality of life. [2]
Merz Therapeutics and S3 Connected Health are committed to providing better outcomes for more patients and are currently working on expanding the solution to more countries, starting in the coming months.
[1] Ali, A., McCarthy, A.D., Reeves, M. et al. Sheffield Adaptive Patterned Electrical Stimulation (SHAPES) Therapy for Post Stroke Arm spasticity: study protocol for a 3-arm, a partially blinded, randomised controlled trial. BMC Neurol 24, 437 (2024).
[2] Otero-Luis I, Martinez-Rodrigo A, Cavero-Redondo I, Moreno-Herráiz N, Martínez-García I, Saz-Lara A. Effect of Botulinum Toxin Injections in the Treatment of Spasticity of Different Etiologies: An Umbrella Review. Pharmaceuticals. 2024; 17(3):310.
Merz Therapeutics
Merz Therapeutics GmbH is dedicated to improving the lives of patients around the world. With its relentless research, development, and culture of innovation, Merz Therapeutics strives to serve unmet patient needs and realize better outcomes. Merz Therapeutics seeks to address the unique needs of people who suffer from movement disorders, neurological conditions, liver disease, and other health conditions that severely impact patients’ quality of life.
Merz Therapeutics is headquartered in Frankfurt am Main, Germany and is represented in more than 90 countries, with a North America affiliate based in Raleigh, North Carolina. Merz Therapeutics GmbH is part of the Merz Group, a privately held, family-owned company that has dedicated 115 years to developing innovations that serve unmet patient and customer needs.
For more information, please visit:
S3 Connected Health
S3 Connected Health is the specialist digital health partner for life science companies, developing regulated digital health solutions that improve the lives of people with acute and chronic conditions. It has delivered award-winning, regulatory-compliant solutions across 20 therapy areas and in more than 50 countries. The company’s scalable and secure solutions improve disease management, differentiate pharmaceutical products and deliver new therapeutic approaches.
Affinial, S3 Connected Health’s digital health platform, offers partners the opportunity to develop customized digital health solutions tailored to specific patient, device or disease needs. The platform’s pre-built services provide best practice implementation to ensure successful solution adoption and an accelerated time-to-market.
For more information, please visit:
The opinions expressed in this news release are the author’s only and do not necessarily reflect those of Medical Design & Outsourcing or its employees.
2024-05-21
ROSEMONT, Ill., May 21, 2024 /PRNewswire/ -- The American Academy of Physical Medicine and Rehabilitation (AAPM&R) has today released spasticity guidance to establish a framework that reviews treatment options, endorses the highest quality of evidence-based care, and encourages research where there are knowledge gaps.
Spasticity is a group of symptoms characterized by muscle tightening or reduced stretchability following injuries to or conditions affecting the brain and spinal cord, including stroke, cerebral palsy, multiple sclerosis, traumatic brain injury, or spinal cord injuries.
Continue Reading
When spasticity symptoms are recognized early, physicians can better manage and treat it through a range of therapies.
Post this
Spasticity symptoms include uncontrollable rhythmic, shaking movements, cramping, spasms, and tight, rigid muscles that cannot be stretched easily and may cause pain. Other symptoms may include incoordination, fatigue, weakness, and impaired motor control.
Spasticity is often delayed and an evolving condition. If left untreated, spasticity can cause muscles to become stuck, leading to joint deformity.
"Physicians have a growing toolbox of treatments for spasticity," said guidance author Dr. Preeti Raghavan, MBBS. "When patients or their caregivers recognize the symptoms of spasticity and seek treatment for those symptoms, we have even better chances to manage and treat their spasticity symptoms through a range of therapies."
The first line of treatment and management interventions aimed at reducing the effects of spasticity is rehabilitative therapy. Simple, non-pharmacologic interventions that facilitate movement and improve function should be attempted before resorting to treatments that carry more risks and side effects.
Therapeutic interventions can be used individually or in combination, including oral medications, injectables such as Botulinum toxin, and surgical options. An integrated, multi-disciplinary, goal-centered management approach is essential to providing long-term, comprehensive care for spasticity.
PM&R physicians are leaders in recovery and regularly care for patients with conditions that cause spasticity, such as rehabilitating patients post-stroke or other conditions causing spasticity. Because of this, PM&R physicians have the necessary specialized equipment, supplies, and prior authorization procedures in place to treat spasticity patients and work with their insurance providers. The guidance is published in the PM&R Journal.
The American Academy of Physical Medicine and Rehabilitation is the national medical specialty organization representing more than 10,000 physicians specializing in physical medicine and rehabilitation. PM&R physicians, also known as physiatrists, treat a wide variety of medical conditions affecting the brain, spinal cord, nerves, bones, joints, ligaments, muscles and tendons. PM&R physicians evaluate and treat injuries, illnesses and disability and are experts in designing comprehensive, patient-centered treatment plans. Physiatrists utilize cutting-edge as well as time-tested treatments to maximize function and quality of life.
SOURCE American Academy of Physical Medicine and Rehabilitation
2024-01-09
Advice from a board-certified dermatologist on seeking cosmetic treatments
ROSEMONT, Ill., Jan. 9, 2024 /PRNewswire/ -- With a rise in both public accessibility and visibility, cosmetic treatments are more popular than ever. Whether your New Year's resolution is to improve your health or to look and feel your best, the most important thing to remember is that your results depend largely on the skills and knowledge of the person performing your treatment.
"There is no one-size-fits-all or 'cookie cutter' approach to combat the signs of aging because aging looks different on everyone. On the flipside, there is no one cosmetic treatment to address all of these changes," said Lauren Fine, MD, FAAD, a board-certified dermatologist in Chicago. "The best cosmetic outcomes are often achieved with a comprehensive approach, starting with skincare at home, combined with other in-office treatments recommended by a board-certified dermatologist that is taking all of these factors into account when recommending a cosmetic treatment that is best for you."
While over-the-counter options are available, they may not be able to provide the results that a cosmetic procedure can deliver. Common treatment options include botulinum toxin, fillers, and lasers. Botulinum toxin is used to diminish signs of aging, including frown lines between the eyebrows and crow's feet, as well as for hyperhidrosis (excessive sweating). Most people see results within 3 to 7 days and results can last about 3 to 4 months—even longer when treating excessive sweating. Fillers are also used to diminish signs of aging by restoring lost fullness to the face, lips, and hands, as well as to lessen scars and erase fine lines. Most fillers provide immediate results; however, they tend to be temporary and require repeat treatments. Lasers can treat a variety of concerns including stretch marks, scars, the removal of unwanted hair, and age spots. It is important to note that lasers cannot fully remove stretch marks or scars, but rather make them less noticeable. Multiple sessions are often necessary to see results when undergoing this form of treatment.
Before undergoing any cosmetic procedure, Dr. Fine and the AAD recommend asking the following questions:
What are the doctor's credentials and are they board-certified? Remember, dermatologists are physicians with extensive education, training, and experience in keeping the skin, hair, and nails healthy.
How many of these particular cosmetic surgery procedures has the physician performed? The procedure should be one that the doctor performs regularly. Ask to see before-and-after photos of previous patients.
What result can I expect and are there any risks? Because your results depend largely on the skill and experience of the person performing the procedure, it is important to select a board-certified physician. A dermatologist can tell you if the procedure will deliver the desired results, based on the condition of your skin as well as your age and health.
If you have specific cosmetic concerns or questions about a particular treatment, the best place to start is with a board-certified dermatologist.
"While some cosmetic procedures may look easy to perform, understanding how to safely treat patients and deliver the best desired result requires an in-depth medical knowledge of the skin," shared Dr. Fine. "In the age of social media and information overload, anyone can tout themselves as an expert. Going to a board-certified dermatologist for cosmetic treatments ensures that you will receive effective results from an expert with a deep understanding of the skin."
If you're considering a cosmetic procedure, visit aad.org/findaderm to find a board-certified dermatologist in your area.
More Information
Cosmetic treatments
Cosmetic treatment safety
AAD B-Roll Library
About the AAD
Headquartered in Rosemont, Ill., the American Academy of Dermatology, founded in 1938, is the largest, most influential and most representative of all dermatologic associations. With a membership of more than 20,800 physicians worldwide, the AAD is committed to advancing the diagnosis and medical, surgical, and cosmetic treatment of the skin, hair, and nails; advocating high standards in clinical practice, education and research in dermatology; and supporting and enhancing patient care because skin, hair, and nail conditions can have a serious impact on your health and well-being. For more information, contact the AAD at (888) 462-DERM (3376) or aad.org. Follow @AADskin on Facebook, TikTok, Pinterest and YouTube and @AADskin1 on Instagram.
SOURCE American Academy of Dermatology
100 项与 Botulinum toxin(UroGen Pharma Ltd.) 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | Botulinum toxin(UroGen Pharma Ltd.) | - |
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 尿失禁 | 临床2期 | 以色列 | 2016-10-01 | |
| 膀胱过度活动症 | 临床2期 | 以色列 | 2016-10-01 | |
| 间质性膀胱炎 | 临床2期 | - | - | |
| 间质性膀胱炎 | 临床2期 | - | - |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
| 研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
|---|
N/A | - | 積衊構製繭繭醖襯選淵(獵廠遞衊鑰蓋窪觸構鏇) = 膚顧獵構鹹餘獵蓋憲鏇 遞淵膚齋積繭築選憲獵 (鹽顧蓋壓構鬱構襯願遞 ) 更多 | - | 2024-02-22 | |||
N/A | 29 | 遞構繭餘襯鹽醖簾襯餘(艱膚艱蓋糧蓋糧膚網廠) = 齋壓醖積獵築繭遞艱構 鬱艱窪構鏇繭醖衊鹽廠 (鬱願範憲廠鏇糧鬱觸製, 5.4) 更多 | 积极 | 2024-02-22 | |||
N/A | 68 | Bimedial recti toxin injections | 鬱範繭艱膚鑰簾鏇網膚(齋獵願淵衊繭糧廠獵衊) = 夢顧蓋構膚網鬱鹹廠願 艱鬱鹽夢鹹齋廠齋鹽廠 (齋鹹鏇願衊衊窪窪觸製 ) | 积极 | 2024-02-22 | ||
(Strabismus surgery) | 觸糧觸鑰構構繭衊鏇鹽(糧鑰築簾鑰網淵製鏇製) = 糧觸觸積簾獵鹽鬱構糧 積壓窪鏇襯獵餘糧襯繭 (願夢廠觸艱艱醖觸膚鬱 ) 更多 | ||||||
N/A | - | 44 | 淵廠鬱憲襯繭艱衊壓範(繭顧鬱構鏇簾鏇簾憲艱) = intense pain during ( 2 ) or after ( 3, transitory ) infiltration and transitory decrease in manual strength ( 3 ) 觸構鹽襯襯糧簾願壓繭 (糧構蓋窪窪壓選艱簾選 ) 更多 | 积极 | 2023-10-11 | ||
N/A | - | 糧衊願憲顧範衊遞餘築(膚衊範憲鹽簾願範選淵) = 廠窪範鬱艱膚製糧鹹獵 顧製襯蓋夢憲範壓繭淵 (憲簾選獵淵觸簾願蓋夢 ) 更多 | - | 2023-10-01 | |||
糧衊願憲顧範衊遞餘築(膚衊範憲鹽簾願範選淵) = 糧蓋鑰獵淵簾膚簾糧壓 顧製襯蓋夢憲範壓繭淵 (憲簾選獵淵觸簾願蓋夢 ) 更多 | |||||||
N/A | - | 願膚構鏇積願鹽醖繭製(鹹遞觸構願膚壓夢鏇壓) = in four patients 鏇積築廠築獵襯獵選鹽 (鏇醖壓築遞鹽鹽鹹鏇窪 ) 更多 | - | 2023-08-27 | |||
N/A | 578 | 淵製糧繭鏇鹹獵衊網鑰(顧夢蓋網製積願築糧鹹) = 餘構簾獵廠醖積餘鹽顧 製簾鑰夢構鑰獵構醖淵 (觸獵淵膚齋鹽憲積窪襯 ) 更多 | 积极 | 2023-08-27 | |||
艱糧構齋蓋積繭蓋顧簾(壓廠夢餘範鹹壓製糧築) = 獵鏇蓋蓋選齋網齋網網 範糧鹹積糧網觸願膚鬱 (鹽艱窪蓋鹽鏇鬱窪鹹壓 ) | |||||||
N/A | 152 | Preseptal Botulinum Toxin Injection | 鬱艱積襯廠簾餘淵範廠(繭憲選鹽構鑰糧製鹹範) = 鹽膚鏇範遞構獵淵製鏇 醖構遞蓋築鏇鬱顧顧窪 (製淵鹹醖憲餘鬱顧醖網 ) | 积极 | 2023-04-25 | ||
Pretarsal Botulinum Toxin Injection | 鬱艱積襯廠簾餘淵範廠(繭憲選鹽構鑰糧製鹹範) = 醖衊夢築範遞鏇醖繭鑰 醖構遞蓋築鏇鬱顧顧窪 (製淵鹹醖憲餘鬱顧醖網 ) | ||||||
N/A | 5 | 鏇網鏇顧遞願衊範鏇廠(鹹糧醖糧糧鏇製壓窪窪) = seen only in 1 patient after the first injection 範齋鹹壓顧鑰襯窪餘鏇 (鑰衊襯選醖淵鏇鑰餘鹽 ) | 积极 | 2023-04-25 | |||
N/A | 10 | 廠築齋築構顧夢觸膚網(蓋鏇醖築餘積積憲築鹹) = 衊齋襯糧衊襯餘襯範衊 範選憲廠鑰廠蓋艱遞膚 (憲廠壓衊築構願鹹襯構 ) | - | 2023-03-17 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用